Rimegepant karamin mai hana kwayoyin cuta necalcitoninMai karɓa na peptide (CGRP) mai alaka da kwayoyin halitta wanda ke toshe aikin CGRP, mai karfin vasodilator ya yi imanin cewa yana taka rawa a cikin ciwon kai na migraine. An yarda da Rimegepant don magance mummunan hare-haren ƙaura. A cikin gwaje-gwajen asibiti, rimegepant gabaɗaya an jure shi da kyau tare da wasu lokuta da ba kasafai kawai ke haifar da hawan jini na aminotransferase ba yayin jiyya kuma ba tare da rahoton raunin hanta a asibiti ba.

Rimegepant antagonist na baka na mai karɓar CGRP wanda Biohaven Pharmaceuticals ya haɓaka. Ya sami amincewar FDA a ranar 27 ga Fabrairu, 2020 don babban maganin ciwon kai. Yayin da yawancin masu adawa da mahaifa na CGRP da mai karɓar sa an yarda da su don maganin migraine (misali [erenumab], [fremanezumab], [galcanezumab]), rimegepant da [ubrogepant] su ne kawai membobin dangin "gepants" na magungunan da suka rage a ci gaba, kuma kawai masu adawa da CGRP waɗanda ke da kwayoyin halitta na baka. Matsayi na yanzu na maganin ƙaura ya ƙunshi maganin zubar da ciki tare da "triptans", kamar [sumatriptan], amma waɗannan magungunan an hana su a cikin marasa lafiya tare da cututtukan cerebrovascular da cututtukan zuciya da suka rigaya sun kasance saboda abubuwan da suke da su na vasoconstrictive. Antagonism na hanyar CGRP ya zama manufa mai ban sha'awa don maganin ciwon kai kamar yadda, sabanin triptans, antagonists na baka CGRP ba su da kaddarorin vasoconstrictive kuma saboda haka sun fi aminci don amfani da marasa lafiya tare da contraindications zuwa daidaitaccen magani.

Rimegepant ni aCalcitoninMai ƙin karɓar karɓa na Peptide mai alaƙa da Gene. Tsarin aikin rimegepant shine aCalcitoninMai ƙin karɓar karɓa na Peptide mai alaƙa da Gene.